Swedish biotechnology company Alligator Bioscience AB (STO:ATORX) announced on Friday that the US Food and Drug Administration (FDA) has endorsed the 900 µg/kg dose of mitazalimab for its upcoming Phase 3 trial targeting metastatic pancreatic ductal adenocarcinoma (mPDAC).
This regulatory feedback affirms the company's dose selection strategy and marks a significant milestone in the clinical development of its CD40 agonist.
According to CEO Søren Bregenholt, the response from the FDA was both timely and constructive.
The company emphasised the importance of this step as it advances its Phase 3 programme in one of the most challenging oncology indications.
Alligator Bioscience is currently engaged in active discussions with potential partners to support the advancement of mitazalimab into late-stage clinical testing.
The planned Phase 3 study represents the next step in the company's strategy to address unmet medical needs in pancreatic cancer.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval